Table 2. Comparing the relative efficacy of therapies with respect to one-year survival status using pairwise and network meta-analysis.
| TACE | TACE +EBRT | TACE +HIFU | TACE +PEI | TACE +RFA | TACE +RT | TACE +SOR | TARE -90Y | DEB-TACE | PAI | PEI | RFA | RT | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TACE | 0.73 (0.56, 0.90) | 0.24 (0.21, 0.28) | 0.48 (0.41, 0.54) | 0.52 (0.39, 0.66) | 0.52 (0.45, 0.60) | 0.47 (0.45, 0.49) | 0.88 (0.80, 0.97) | 0.51 (0.46, 0.57) | - | 0.91 (0.78, 1.04) | 0.84 (0.67, 1.00) | 0.42 (0.32, 0.52) | |
| TACE+EBRT | 0.73 (0.30, 1.75) | - | - | - | - | - | - | - | - | - | - | - | |
| TACE+HIFU | 0.31 (0.17, 0.57) | 0.42 (0.14, 1.22) | - | - | - | - | - | - | - | - | - | - | |
| TACE+PEI | 0.72 (0.47, 1.09) | 0.99 (0.37, 2.60) | 2.35 (1.12, 4.95) | - | - | - | - | - | - | 2.04 (1.69, 2.56) | |||
| TACE+RFA | 0.45 (0.28, 0.72) | 0.62 (0.23, 1.67) | 1.48 (0.68, 3.21) | 0.63 (0.34, 1.15) | - | - | - | - | - | - | 2.13 (1.92, 2.44) | ||
| TACE+RT | 0.41 (0.25, 0.66) | 0.56 (0.21, 1.51) | 1.33 (0.61, 2.90) | 0.56 (0.30, 1.07) | 0.90 (0.46, 1.76) | - | - | - | - | - | - | 6.25 (5.00, 8.33) | |
| TACE+SOR | 0.55 (0.37, 0.83) | 0.76 (0.29, 1.99) | 1.80 (0.86, 3.78) | 0.77 (0.43, 1.38) | 1.22 (0.65, 2.28) | 1.36 (0.72, 2.56) | - | - | - | - | - | - | |
| TARE-90Y | 0.88 (0.57, 1.35) | 1.20 (0.45, 3.19) | 2.86 (1.35, 6.07) | 1.22 (0.67, 2.22) | 1.93 (1.02, 3.67) | 2.15 (1.13, 4.12) | 1.59 (0.87, 2.89) | - | - | - | - | - | |
| DEB-TACE | 0.73 (0.53, 1.00) | 0.99 (0.39, 2.53) | 2.37 (1.18, 4.75) | 1.01 (0.59, 1.71) | 1.60 (0.91, 2.84) | 1.79 (1.00, 3.19) | 1.32 (0.78, 2.22) | 0.83 (0.48, 1.42) | - | - | - | - | |
| PAI | 1.00 (0.34, 2.91) | 1.37 (0.34, 5.44) | 3.27 (0.95, 11.19) | 1.39 (0.46, 4.19) | 2.21 (0.74, 6.63) | 2.46 (0.76, 7.93) | 1.81 (0.58, 5.69) | 1.14 (0.36, 3.61) | 1.38 (0.45, 4.20) | 1.33 (0.90, 2.56) | - | - | |
| PEI | 1.33 (0.84, 2.13) | 1.83 (0.68, 4.92) | 4.35 (2.01, 9.42) | 1.85 (1.07, 3.19) | 2.95 (1.72, 5.04) | 3.28 (1.68, 6.41) | 2.42 (1.30, 4.50) | 1.52 (0.80, 2.88) | 1.84 (1.04, 3.24) | 1.33 (0.51, 3.48) | 0.30 (0.20, 0.41) | - | |
| RFA | 0.87 (0.57, 1.32) | 1.19 (0.45, 3.13) | 2.83 (1.34, 5.95) | 1.20 (0.70, 2.08) | 1.91 (1.27, 2.88) | 2.13 (1.13, 4.03) | 1.57 (0.87, 2.82) | 0.99 (0.54, 1.81) | 1.19 (0.70, 2.02) | 0.87 (0.31, 2.45) | 0.65 (0.44, 0.97) | - | |
| RT | 1.03 (0.53, 2.01) | 1.41 (0.47, 4.24) | 3.37 (1.36, 8.34) | 1.43 (0.65, 3.15) | 2.28 (1.01, 5.15) | 2.54 (1.30, 4.94) | 1.87 (0.85, 4.09) | 1.18 (0.53, 2.61) | 1.42 (0.68, 2.98) | 1.03 (0.29, 3.63) | 0.77 (0.34, 1.75) | 1.19 (0.54, 2.62) |
1. The cells in blue are results of pair-wise meta-analysis and the column treatment is compared with the row treatment. The results are presented by hazard ratio (HR) and 95% credible interval (CrI). The cells in red are results of network meta-analysis and the row treatment is compared with the column treatment. The results are presented by hazard ratio (HR) and 95% credible interval (CrI).
2. TACE: transcatheter arterial chemoembolization; EBRT: external-beam radiation therapy; HIFU: high intensity focused ultrasound; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation; RT: radiotherapy; SOR: sorafenib; TARE-90Y: yttrium-90 radioembolization; DEB-TACE: drug-eluting beads-transcatheter arterial chemoembolization; PAI: percutaneous acetic acid injection.